Scholarlink

Objective <p>The rising incidence of spondylodiscitis (SD) poses a challenge to healthcare systems worldwide. Treatment approaches are inconsistent, devoid of standardized algorithms and lack evidence-based guidelines. To date there is a knowledge gap relative to treatment, readmission rates and efficacy for different SD management strategies. This study aims to assess the 90-day all-cause readmission rates for SD relative to treatment pathways.</p> Methods <p>Using the 2020 Nationwide Readmissions Database we screened adult patients (&gt; 18 years) for primary diagnosis of SD by ICD-10 Codes. Demographic/clinical data, and treatments was extracted. The cohort was divided into two groups by treatment at initial admission. Descriptive and comparative analysis, with a multivariate regression to identify independent risk factors for readmission, were performed.</p> Results <p>Out of 6,139 patients, 1,258 patients (20.5%) receiving surgical treatment. The overall, readmission rate was 35%. Surgically treated patients had a significantly lower readmission rate and a shorter time to readmission (29.3%; 41.65 days (± 22.84)). Those receiving surgical care during both stays (0.8%) had the longest time to readmission at 50.85 days (± 24.27). A change in treatment upon readmission was observed in 8.4%. Surgical management at index admission was identified as a protective factor against readmission.</p> Conclusion <p>SD management remains challenging. We showed that primary surgical treatment of SD resulted in a significantly lower readmission rate with a longer time interval until readmission compared to non-surgically treatment. Surgery at initial admission was identified as a protective factors against readmission. A more definitive initial approach towards SD might lower unexpected readmissions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The conundrum of finding an optimal spondylodiscitis treatment pathway: how do treatments affect readmission rates?

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月26日

查看全文
  • Julius Gerstmeyer,
  • Clifford Pierre,
  • Neel Patel,
  • Donald David Davis,
  • Jonathan Pluemer,
  • Thomas A. Schildhauer,
  • Amir Abdul-Jabbar,
  • Rod J. Oskouian,
  • Jens R. Chapman

摘要

Objective

The rising incidence of spondylodiscitis (SD) poses a challenge to healthcare systems worldwide. Treatment approaches are inconsistent, devoid of standardized algorithms and lack evidence-based guidelines. To date there is a knowledge gap relative to treatment, readmission rates and efficacy for different SD management strategies. This study aims to assess the 90-day all-cause readmission rates for SD relative to treatment pathways.

Methods

Using the 2020 Nationwide Readmissions Database we screened adult patients (> 18 years) for primary diagnosis of SD by ICD-10 Codes. Demographic/clinical data, and treatments was extracted. The cohort was divided into two groups by treatment at initial admission. Descriptive and comparative analysis, with a multivariate regression to identify independent risk factors for readmission, were performed.

Results

Out of 6,139 patients, 1,258 patients (20.5%) receiving surgical treatment. The overall, readmission rate was 35%. Surgically treated patients had a significantly lower readmission rate and a shorter time to readmission (29.3%; 41.65 days (± 22.84)). Those receiving surgical care during both stays (0.8%) had the longest time to readmission at 50.85 days (± 24.27). A change in treatment upon readmission was observed in 8.4%. Surgical management at index admission was identified as a protective factor against readmission.

Conclusion

SD management remains challenging. We showed that primary surgical treatment of SD resulted in a significantly lower readmission rate with a longer time interval until readmission compared to non-surgically treatment. Surgery at initial admission was identified as a protective factors against readmission. A more definitive initial approach towards SD might lower unexpected readmissions.